16495-03-7

Basic information

• Product Name: (S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE
• Synonyms: 1,3-Dioxolane, 2,2-diMethyl-4-[(phenylMethoxy)Methyl]-, (4S)-;3-O-BENZYL-1,2-O-ISOPROPYLIDENE-SN-GLYCEROL;3-BENZYL-1,2-ISOPROPYLIDENE-SN-GLYCEROL;D-ALPHA,BETA-ISOPROPYLIDENEGLYCEROL-GAMMA-BENZYL ETHER;(S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE;(S)-1-BENZYL-2,3-O-ISOPROPYLIDENE GLYCEROL;3-Benzyl-1,2-isopropylidene-sn-glycerol, D-α,β-Isopropylideneglycerol-γ-benzyl ether
• CAS NO: 16495-03-7
• Molecular Formula: C₁₃H₁₈O₃
• Molecular Weight: 222.28
• Product Categories: Aromatics;Chiral Reagents;Chiral Building Blocks;Dioxanes & Dioxolanes;Dioxolanes;Glycidyl Compounds, etc. (Chiral);Synthetic Organic Chemistry;Fatty Acid Derivatives & Lipids;Glycerols
• Mol File: 16495-03-7.mol

Chemical Properties

• Boiling Point: 79-80 °C0.05 mm Hg(lit.)
• Flash Point: 100 °C
• Appearance: clear yellow oil
• Density: 1.050 g/mL at 20 °C(lit.)
• Refractive Index: n20/D 1.496
• Storage Temp.: 2-8°C
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: (S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE(16495-03-7)
• EPA Substance Registry System: (S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE(16495-03-7)

Safety Data

• Safety Statements: 23-24/25
• WGK Germany: 3
• F: 10-23
• Hazardous Substances Data: 16495-03-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE is used as a key intermediate in the synthesis of the analogs of dioxolanes Dexoxadrol and Etoxadrol. These analogs are considered potential phencyclidine-like agents, which may have applications in the development of new medications for various therapeutic purposes.
Chemical Properties:
(S)-4-BENZYLOXYMETHYL-2,2-DIMETHYL-1,3-DIOXOLANE is a clear yellow oil, which indicates its liquid state at room temperature and its characteristic color. This property can be useful for identifying the compound during synthesis and purification processes.

InChI:InChI=1/C13H18O3/c1-13(2)10-15-12(16-13)9-14-8-11-6-4-3-5-7-11/h3-7,12H,8-10H2,1-2H3/t12-/m0/s1

Upstream product

• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 
• 77-76-9 2,2-dimethoxy-propane 
• 2930-05-4 Benzyloxymethyl-oxiran 
• 118509-02-7 Acetic acid (R)-2-benzyloxy-1-hydroxymethyl-ethyl ester 
• 118508-98-8 (4S,5S)-4,5-O-isopropylidene-1,8-di-O-benzyl-2E,6E-octadiene-1,4,5,8-tetraol 
• 118508-99-9 (4S,5S)-1,8-di-O-benzyl-2E,6E-octadiene-1,4,5,8-tetraol 
• 185025-19-8 Acetic acid (2E,5E)-(1R,4S)-4-acetoxy-7-benzyloxy-1-benzyloxymethyl-hepta-2,5-dienyl ester 
• 118509-01-6 (2R,7R)-2,7-di-O-acetyl-1,8-di-O-benzyl-23,5E-octadiene-1,2,7,8-tetraol 
• 100-39-0 benzyl bromide 
• 100-79-8 2,3-O-isopropylidene glycerol 
• 10567-18-7 (+/-)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl n-octadecanoate 
• 20620-19-3 (2,2-dimethyl-1,3-dioxolane-4-yl)methyl caproate 
• 10567-18-7 (R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl n-octadecanoate 

Downstream Products

• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 
• 83526-68-5 (S)-1-(benzyloxy)-3-trityloxypropan-2-ol 
• 203261-33-0 Octanedioic acid allyl ester (S)-1-benzyloxymethyl-2-trityloxy-ethyl ester 
• 77697-15-5 (R)-(-)-γ-benzyloxymethyl-γ-butyrolactone 
• 77697-13-3 (R)-(-)-γ-benzyloxymethyl-(R/S)-α-carbenoxy-γ-butyrolactone 
• 99298-07-4 1-O-(tert-butyldiphenylsilyl)-3-O-benzyl-sn-glycerol 
• 118917-64-9 (R)-2,2'-((3-(benzyloxy)propane-1,2-diyl)bis(oxy))bis(ethan-1-ol) 
• 120362-28-9 {1-Benzyloxymethyl-2-[(4-methoxy-phenyl)-diphenyl-methoxy]-ethoxymethyl}-phosphonic acid diethyl ester 
• 120362-34-7 [2-(4-Amino-pyrimidin-2-yloxy)-1-benzyloxymethyl-ethoxymethyl]-phosphonic acid diethyl ester 
• 120362-33-6 (S)-1-<3-(Benzyloxy)-2-<(diethylphosphonyl)methoxy>propyl>cytosine 
• 120362-27-8 1-Benzyloxy-3-[(4-methoxy-phenyl)-diphenyl-methoxy]-propan-2-ol 
• 120362-30-3 Methanesulfonic acid 3-benzyloxy-2-(diethoxy-phosphorylmethoxy)-propyl ester 
• 120362-29-0 (2-Benzyloxy-1-hydroxymethyl-ethoxymethyl)-phosphonic acid diethyl ester 
• 4799-67-1 3-O-benzylglycerol 

Relevant articles and documents

Synthesis of enantiomerically pure (R)-and (S)-1-benzoyloxypropane-2,3-diol and revision of the stereochemical outcome of the Candida antarctica lipase-catalyzed benzoylation of glycerol

Enantiomerically pure (R)- and (S)-1-benzoyloxypropane-2,3-diol have been prepared from (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol and used as reference compounds to correct the reported stereochemical outcome of the Candida antarctica lipase (CAL)-cat

The Chiral Target of Daptomycin Is the 2R,2′S Stereoisomer of Phosphatidylglycerol

Daptomycin (dap) is an important antibiotic that interacts with the bacterial membrane lipid phosphatidylglycerol (PG) in a calcium-dependent manner. The enantiomer of dap (ent-dap) was synthesized and was found to be 85-fold less active than dap against

Investigating the Individual Importance of the Pam2Cys Ester Motifs on TLR2 Activity

TLR2 agonists are at the forefront of vaccine research for a plethora of diseases, in particular they offer a promising tool for the treatment of cancer. A detailed knowledge of their structure–activity relationship informs the methodical design of vaccin

Preparation, supramolecular aggregation and immunological activity of the bona fide vaccine adjuvant sulfavant S

In aqueous conditions, amphiphilic bioactive molecules are able to form self-assembled colloidal structures modifying their biological activity. This behavior is generally neglected in preclinical studies, despite its impact on pharmacological development. In this regard, a significative example is represented by a new class of amphiphilic marine-inspired vaccine adjuvants, collectively named Sulfavants, based on the β-sulfoquinovosyl-diacylglyceride skeleton. The family includes the lead product Sulfavant A (1) and two epimers, Sulfavant R (2) and Sulfavant S (3), differing only for the stereochemistry at C-2 of glycerol. The three compounds showed a significant difference in immunological potency, presumably correlated with change of the aggregates in water. Here, a new synthesis of diastereopure 3 was achieved, and the study of the immunomodulatory behavior of mixtures of 2/3 proved that the bizarre in vitro response to 1–3 effectively depends on the supramolecular aggregation states, likely affecting the bioavailability of agonists that can effectively interact with the cellular targets. The evidence obtained with the mixture of pure Sulfavant R (2) and Sulfavant S (3) proves, for the first time, that supramolecular organization of a mixture of active epimers in aqueous solution can bias evaluation of their biological and pharmacological potential.

MACROCYCLIC CHELATORS AND METHODS OF USE THEREOF

Macrocyclic chelators (I) for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Synthesis of enantiopure ABC-type triacylglycerols

The synthesis of twelve enantiopure structured triacylglycerols (TAGs) of the ABC type possessing three different fatty acids is described by a six-step chemoenzymatic approach starting from (S)-solketal. Eight of the TAGs possess two different saturated fatty acyl groups located in the sn-1 and sn-2 positions with an unsaturated fatty acyl group in the remaining sn-3 position of the glycerol skeleton, whereas the remaining four possess two different saturated acyl groups in the terminal sn-1 and sn-3 positions with an unsaturated acyl group in the sn-2 position. The former group was synthesised by a six-step chemoenzymatic route involving a highly regioselective immobilised Candida antarctica lipase. The second group was prepared by a similar six-step approach, that required two separate lipase steps. Such enantiopure TAGs are strongly demanded as standards for enantiospecific analysis of intact TAGs in fats and oils.

COMPOUNDS, DERIVATIVES, AND ANALOGS FOR CANCER

The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. T

Synthesis and enantiospecific analysis of enantiostructured triacylglycerols containing n-3 polyunsaturated fatty acids

The stereospecific structure of triacylglycerols (TAGs) affects the bioavailability of fatty acids. Lack of enantiopure reference compounds and effective enantiospecific methods have hindered the stereospecific analysis of individual TAGs. Twelve novel enantiostructured AAB-type TAGs were synthesized containing one of the three n-3 polyunsaturated fatty acid: α-linolenic acid (ALA), eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA) in sn-1 or sn-3 position. These compounds formed six enantiomer pairs, which were separated with recycling high-performance liquid chromatography using chiral columns and UV detection. The chromatographic retention behavior of the enantiomers and the stereospecific elution order were studied. The enantiomer with an n-3 PUFA in the sn-1 position eluted faster than the enantiomer with the n-3 PUFA in the sn-3 position, regardless of the carbon chain length and number of double bonds of the PUFA. TAG enantiomers containing DHA exhibited highly different retention on the chiral column and were separated after the first column, whereas recycling was needed to separate the enantiomer pairs containing ALA or EPA. The system using two identical columns and one mobile phase, without sample derivatization, proved to be very effective also for peak purity assessment, confirming the enantiopurity of the synthesized structured TAGs being higher than 98 percent (96 percent ee).

H-Phosphonate Synthesis and Biological Evaluation of an Immunomodulatory Phosphoglycolipid from Thermophilic Bacteria

The synthesis of a library of bacterial phosphoglycolipid, PGL-1, is described. Key features of the synthesis include regioselective esterification of the primary alcohol of the diacylglycerol moiety and an H-phosphonate method to install the phosphate in PGL-1 in comparison with earlier reported procedures. A representative set of PGL-1 analogues was prepared and evaluated for their biological activities. Results showed that the immunological activity of PGL-1 is dependent on the chain lengths of the fatty acids.

PHOSPHOLIPID COMPOUND CONTAINING UNSATURATED FATTY ACID DERIVATIVE HAVING CYCLOPROPANE RING

The present invention aims to provide a medicine having a cognitive function improving effect and an anti-diabetes action. A phospholipid compound containing unsaturated fatty acid having a cyclopropane ring such as 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) and 8-(2-octylcyclopropyl)octanoic acid (DCP-OA) and the like, particularly 1,2-o-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidylethanolamine (diDCP-LA-PE), has a cognitive function improving effect and an anti-diabetes action, and is useful as a medicine such as a therapeutic drug for dementia, a therapeutic drug for diabetes and the like.